CytoSorbents Corp (CTSO)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.35+0.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · CTSO
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | 37.1 | 35.6 | 31.1 | 34.7 | 43.2 | 41.0 | 24.9 | 22.5 | 15.2 | 9.5 | 4.8 | 4.1 | 2.4 | 1.3 | 0.0 |
| Total Revenues | — | — | — | — | — | — | — | — | 22.5 | 15.2 | 9.5 | 4.8 | 4.1 | 2.4 | 1.3 | 0.0 |
| Cost of Revenues | 10.6 | 10.6 | 10.5 | 9.1 | 14.0 | 11.0 | 11.1 | 7.4 | 7.5 | — | — | — | — | — | — | — |
| Gross Profit | 26.6 | 26.5 | 25.1 | 22.0 | 20.7 | 32.1 | 30.0 | 17.6 | 15.0 | 9.6 | 5.6 | 2.6 | 2.0 | 0.5 | 1.0 | 0.0 |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 34.2 | 35.6 | 35.0 | 38.3 | 34.3 | 35.8 | 28.5 | 22.0 | 20.9 | 14.9 | 11.8 | 6.9 | 5.6 | 2.6 | 1.4 | — |
| R&D Expenses | — | — | — | 15.7 | 15.1 | 16.4 | 8.8 | 12.1 | 7.7 | 3.2 | 4.1 | 3.9 | 2.4 | 1.7 | 2.5 | 2.9 |
| Operating Income | (12.9) | (14.7) | (16.8) | (31.9) | (31.5) | (22.7) | (10.4) | (19.0) | (15.6) | (9.8) | (11.5) | (9.3) | (6.9) | (4.7) | (3.5) | (4.4) |
| Earnings from Continuing Operations | ||||||||||||||||
| Other Non-Operating Income / Expenses | (5.7) | 6.2 | (5.6) | 1.9 | (2.4) | (2.5) | 1.4 | (1.4) | (2.2) | 0.7 | (0.6) | (0.5) | (2.8) | (0.4) | (0.6) | (1.0) |
| EBT, Incl. Unusual Items | — | (8.6) | (22.4) | (30.1) | (33.9) | (25.3) | (9.0) | (20.4) | (17.8) | (9.1) | (12.1) | (9.8) | (9.7) | (5.1) | (4.1) | (5.5) |
| Income Tax Expense | — | (0.4) | (1.7) | (0.8) | (1.1) | (0.7) | (1.1) | (1.1) | (0.6) | (0.7) | (0.3) | (0.3) | (0.4) | (0.5) | (0.4) | — |
| Net Income | ||||||||||||||||
| Net Income | (18.2) | (8.2) | (20.7) | (29.2) | (32.8) | (24.6) | (7.8) | (19.3) | (17.2) | (8.5) | (11.8) | (9.5) | (9.3) | (4.7) | (3.7) | (5.5) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.29) | (0.13) | (0.38) | (0.65) | (0.75) | (0.57) | (0.20) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (0.29) | (0.13) | (0.38) | (0.65) | (0.75) | (0.57) | (0.20) | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 62.8 | 62.2 | 54.4 | 44.7 | 43.6 | 43.4 | 38.8 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 62.8 | 62.2 | 54.4 | 44.7 | 43.6 | 43.4 | 38.8 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (13.5) | (15.2) | (30.5) | (30.6) | (22.0) | (9.7) | (18.4) | (15.2) | (9.6) | (11.3) | (9.2) | (6.8) | (4.6) | (3.4) | (4.4) |
| EBIT | (12.9) | (14.7) | (16.8) | (31.9) | (31.5) | (22.7) | (10.4) | (19.0) | (15.6) | (9.8) | (11.5) | (9.3) | (6.9) | (4.7) | (3.5) | (4.4) |
| Effective Tax Rate | — | — | — | 2.7% | 3.2% | 2.9% | 12.6% | 5.4% | 3.5% | 7.4% | 2.6% | 3.3% | 4.0% | 8.9% | 9.7% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.